• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中和 SARS-CoV-2 奥密克戎亚谱系 BA.1、BA.1.1 和 BA.2.

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.

机构信息

Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA.

Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA.

出版信息

Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25.

DOI:10.1016/j.chom.2022.04.014
PMID:35526534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9035359/
Abstract

Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicron sub-lineages, including BA.2, are comparably neutralized by Omicron patient sera. These results highlight the importance of booster vaccine doses for protection against all Omicron variants and provide insight into the immunity from natural infection against Omicron sub-lineages.

摘要

最近有关 SARS-CoV-2 奥密克戎变异株亚谱系 BA.1、BA.1.1 和 BA.2 的报告再次引发了人们对疫苗和感染诱导的免疫可能逃逸的担忧。我们研究了这些亚谱系以及其他主要变体对 mRNA 疫苗接种和加强免疫个体以及已康复的 COVID-19 患者(包括感染奥密克戎的患者)产生的中和抗体的敏感性。我们发现,所有奥密克戎亚谱系,特别是 BA.1 和 BA.1.1,都表现出显著的免疫逃逸,而 mRNA 疫苗加强剂量在很大程度上克服了这种逃逸。虽然奥密克戎 BA.1.1 几乎完全逃避了早期大流行期间 COVID-19 患者血清和在较小程度上逃避了感染德尔塔变异株患者血清的中和作用,但 BA.1.1 对奥密克戎感染患者血清敏感。至关重要的是,所有奥密克戎亚谱系,包括 BA.2,都被奥密克戎患者血清同等中和。这些结果强调了加强疫苗剂量对预防所有奥密克戎变体的重要性,并提供了对自然感染奥密克戎亚谱系免疫的深入了解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/61d2cb1e0984/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/2f3db010df22/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/2663e6d1b812/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/ad6e42478f83/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/61d2cb1e0984/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/2f3db010df22/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/2663e6d1b812/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/ad6e42478f83/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a61/9035359/61d2cb1e0984/gr3_lrg.jpg

相似文献

1
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.中和 SARS-CoV-2 奥密克戎亚谱系 BA.1、BA.1.1 和 BA.2.
Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25.
2
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.初次感染 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 株后中和抗体的不同反应特征
Front Immunol. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318. eCollection 2022.
3
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
4
Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.SARS-CoV-2 奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 亚谱系的抗体逃逸。
Cell Host Microbe. 2022 Aug 10;30(8):1077-1083.e4. doi: 10.1016/j.chom.2022.05.001. Epub 2022 May 8.
5
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.
6
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.由 COVID-19 mRNA 疫苗诱导的抗体对 SARS-CoV-2 变体的差异中和与抑制作用。
Nat Commun. 2022 Jul 27;13(1):4350. doi: 10.1038/s41467-022-31929-6.
7
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.三剂 BNT162b2 疫苗或 BA.1 感染对奥密克戎亚谱系和德尔塔克戎 SARS-CoV-2 的中和作用。
Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305.
8
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.mRNA 或基于载体的 COVID-19 疫苗接种后对 SARS-CoV-2 奥密克戎变异株的中和反应减弱。
Sci Rep. 2022 Nov 18;12(1):19858. doi: 10.1038/s41598-022-22552-y.
9
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.第三剂 COVID-19 mRNA 疫苗接种后针对奥密克戎变异株的持续 T 细胞介导的免疫应答。
Front Immunol. 2023 Jan 23;14:1099246. doi: 10.3389/fimmu.2023.1099246. eCollection 2023.
10
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.含有 D614G 和 BA.1 刺突三聚体蛋白的二价疫苗或 BA.1 刺突三聚体蛋白加强针可产生广泛的中和免疫。
J Med Virol. 2022 Sep;94(9):4287-4293. doi: 10.1002/jmv.27885. Epub 2022 Jun 2.

引用本文的文献

1
SARS-CoV-2 vaccines elicit differential Fc effector functions.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)疫苗引发不同的Fc效应器功能。
iScience. 2025 Jul 9;28(8):113084. doi: 10.1016/j.isci.2025.113084. eCollection 2025 Aug 15.
2
Behavioral Dynamics, Genomic Insights, and Social Drivers of SARS-CoV-2 Waves and Variants in Cali, Colombia (2020-2023).哥伦比亚卡利市新冠病毒(SARS-CoV-2)疫情波次与变体的行为动态、基因组洞察及社会驱动因素(2020 - 2023年)
Viruses. 2025 May 30;17(6):800. doi: 10.3390/v17060800.
3
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections.

本文引用的文献

1
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.mRNA 或基于载体的 COVID-19 疫苗接种后对 SARS-CoV-2 奥密克戎变异株的中和反应减弱。
Sci Rep. 2022 Nov 18;12(1):19858. doi: 10.1038/s41598-022-22552-y.
2
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.疫苗突破性感染导致 SARS-CoV-2 变异株的中和抗体应答呈现出不同的特征。
JCI Insight. 2022 Oct 10;7(19):e159944. doi: 10.1172/jci.insight.159944.
3
Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
内在免疫原性是新冠病毒感染中型特异性反应的主要决定因素。
Nat Immunol. 2025 May 27. doi: 10.1038/s41590-025-02162-2.
4
Electronic Interactions Between the Receptor-Binding Domain of Omicron Variants and Angiotensin-Converting Enzyme 2: A Novel Amino Acid-Amino Acid Bond Pair Concept.奥密克戎变异株受体结合域与血管紧张素转换酶2之间的电子相互作用:一种新型氨基酸-氨基酸键对概念
Molecules. 2025 May 6;30(9):2061. doi: 10.3390/molecules30092061.
5
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代:SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
6
A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern.一种表达稳定不可切割刺突蛋白的基于重组DNA的改良型SARS-CoV-2疫苗可引发针对多种SARS-CoV-2变异株的体液免疫和细胞免疫。
Transbound Emerg Dis. 2023 Dec 11;2023:5279979. doi: 10.1155/2023/5279979. eCollection 2023.
7
Beyond COVID-19: the promise of next-generation coronavirus vaccines.超越新冠疫情:下一代冠状病毒疫苗的前景
Npj Viruses. 2024 Aug 22;2(1):39. doi: 10.1038/s44298-024-00043-3.
8
Estimating the Waning Effectiveness of COVID-19 Vaccines From Population-Level Surveillance Data in Hong Kong.根据香港的人口层面监测数据评估2019冠状病毒病疫苗的效力衰减情况
J Infect Dis. 2025 Aug 14;232(2):e341-e345. doi: 10.1093/infdis/jiaf207.
9
Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants.JN.1衍生的LB.1、KP.2.3、KP.3和KP.3.1.1亚变体的中和作用及刺突稳定性
mBio. 2025 May 14;16(5):e0046425. doi: 10.1128/mbio.00464-25. Epub 2025 Mar 26.
10
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
在 SARS-CoV-2 异质感染和接种人群中,抗体和记忆 B 细胞免疫。
mBio. 2022 Aug 30;13(4):e0084022. doi: 10.1128/mbio.00840-22. Epub 2022 Jun 23.
4
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters.奥密克戎变异株在仓鼠中致病性降低。
Med. 2022 Apr 8;3(4):262-268.e4. doi: 10.1016/j.medj.2022.03.004. Epub 2022 Mar 17.
5
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1和BA.2变体的中和作用
N Engl J Med. 2022 Apr 21;386(16):1579-1580. doi: 10.1056/NEJMc2201849. Epub 2022 Mar 16.
6
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后,SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
7
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2.两剂或三剂 BNT162b2 疫苗对奥密克戎 SARS-CoV-2 的中和作用和持久性。
Cell Host Microbe. 2022 Apr 13;30(4):485-488.e3. doi: 10.1016/j.chom.2022.02.015. Epub 2022 Feb 18.
8
Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain.新冠病毒奥密克戎变异株刺突蛋白胞外域的冷冻电镜结构
Nat Commun. 2022 Mar 3;13(1):1214. doi: 10.1038/s41467-022-28882-9.
9
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant.一种泛沙贝病毒疫苗在非人灵长类动物中诱导出针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变体的高效且持久的中和抗体反应。
Cell Res. 2022 May;32(5):495-497. doi: 10.1038/s41422-022-00631-z. Epub 2022 Feb 24.
10
Cryo-EM structure of the SARS-CoV-2 Omicron spike.SARS-CoV-2 奥密克戎刺突蛋白的冷冻电镜结构。
Cell Rep. 2022 Mar 1;38(9):110428. doi: 10.1016/j.celrep.2022.110428. Epub 2022 Feb 7.